Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Samuel O. Antwi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2372-9489; OpenAlex author ID A5017787897. Sources: ClinicalTrials.gov.

Their work

Papers
25 (first author 0, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 5 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 6 papers, 1 trial

Papers 25

  1. Germline Variants in Chronic Pancreatitis-Associated Genes and Risk of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cgh.2026.03.043↗
  2. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  3. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  4. Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer. Last author DOI 10.1371/journal.pone.0343022↗
  5. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  6. Mutational signature landscape of pancreatic cancer genomes from nine countries Co-author DOI 10.64898/2026.10.21.26365999↗
  7. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  8. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Last author DOI 10.1530/erc-24-0142↗
  9. Bulk RNA-seq deconvolution heterogeneity across paired pancreatic cancer human samples. Co-author DOI 10.3389/fgene.2025.1662924↗
  10. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  11. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Last author DOI 10.1158/1055-9965.epi-23-0453↗
  12. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. Co-author DOI 10.1158/1055-9965.epi-21-0745↗
  13. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  14. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Co-author DOI 10.1158/1055-9965.epi-19-1597↗
  15. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  16. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Co-author DOI 10.1093/jnci/djx272↗
  17. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. Co-author DOI 10.1001/jama.2018.6228↗
  18. Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Co-author DOI 10.1002/ijc.31271↗
  19. Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Co-author DOI 10.1093/carcin/bgy072↗
  20. Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review. Co-author DOI 10.1097/mpa.0000000000000995↗
  21. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Co-author DOI 10.1158/1055-9965.epi-17-1065↗
  22. Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-17-0100↗
  23. Telomere Length and Pancreatic Cancer Risk-Reply. Co-author DOI 10.1158/1055-9965.epi-17-0307↗
  24. Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. Co-author DOI 10.1093/carcin/bgw022↗
  25. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Co-author DOI 10.1007/s10552-015-0652-y↗

Trials 1

  1. Prospective Familial Registry for Pancreas Research Principal investigator NCT07358208↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kari G. Rabe · 13 shared papers, 2015–2026 · strength 1.64
  2. Ann L. Oberg · 10 shared papers, 2015–2026 · strength 1.19
  3. Gloria M. Petersen · 12 shared papers, 2015–2022 · strength 1.11
  4. Hugues Sicotte · 5 shared papers, 2018–2026 · strength 0.89
  5. Ryan Michael Carr · 2 shared papers, 2025–2026 · strength 0.49
  6. Lisa A. Boardman · 4 shared papers, 2017–2021 · strength 0.42
  7. Shruti Chandra · 2 shared papers, 2022–2025 · strength 0.36
  8. Robert R. McWilliams · 4 shared papers, 2018–2022 · strength 0.35
  9. Amit Mahipal · 2 shared papers, 2021–2025 · strength 0.35
  10. Rick J. Jansen · 1 shared paper, 2025 · strength 0.33
  11. Laufey Thora Amundadottir · 2 shared papers, 2018–2026 · strength 0.32
  12. Aminah Jatoi · 3 shared papers, 2017–2021 · strength 0.31
  13. Chunling Hu · 3 shared papers, 2018–2022 · strength 0.29
  14. Fergus Joseph Couch · 3 shared papers, 2018–2022 · strength 0.29
  15. Jason W. Hoskins · 1 shared paper, 2026 · strength 0.27
  16. Katelyn E. Connelly · 1 shared paper, 2026 · strength 0.27
  17. Khalid Jazieh · 1 shared paper, 2026 · strength 0.27
  18. Thorvardur Ragnar Halfdanarson · 1 shared paper, 2025 · strength 0.22
  19. Sean Patrick Cleary · 1 shared paper, 2025 · strength 0.22
  20. Shounak Majumder · 1 shared paper, 2025 · strength 0.22
  21. James R. Hébert · 3 shared papers, 2016–2018 · strength 0.19
  22. Nitin Shivappa · 3 shared papers, 2016–2018 · strength 0.19
  23. Susan E. Steck · 3 shared papers, 2016–2018 · strength 0.19
  24. Rachael Z. Stolzenberg‐Solomon · 2 shared papers, 2018 · strength 0.13
  25. Wei Zheng · 2 shared papers, 2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.